Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's lead drug candidate, tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase, in clinical development for the treatment of patients with solid tumors harboring HRAS mutations.